Compare T-Mobile Us Inc (TMUS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs State Street SPDR S&P Biotech ETF — how do they compare? T-Mobile Us Inc trades at $190.25 (market cap $211.72B), while State Street SPDR S&P Biotech ETF trades at $154.38. The key difference: T-Mobile Us Inc pays a 2.09% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, T-Mobile Us Inc nearer its low. Which is the better fit depends on your goals.
| TMUS | XBI | |
|---|---|---|
Market Cap | $211.72B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $259.01 | $164.28 |
52-Week Low | $167.65 | $85.16 |
Enterprise Value | $329.42B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T-Mobile (TMUS) trades at $190.64, down 0.93% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings near 85. The company demonstrates robust fundamentals with 2025 revenue of $88.31 billion and net income of $10.99 billion, though profit margins have moderated from 13.92% in 2024 to 12.44% in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending.
T-Mobile presents a compelling growth story in telecom with strong analyst support (83% buy ratings) and a $237.40 consensus price target implying 25% upside. Key risks include increasing debt-to-asset ratios (39.35% in 2025) and competitive pressures from satellite internet providers. The stock's current valuation at 20.79 P/E appears reasonable given growth prospects, though investors should monitor execution on subscriber and broadband growth targets.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
